IGF-1 LR3

IGF-1 LR3 (Long R3 IGF-1) is a modified version of human insulin-like growth factor-1 with an arginine substitution at position 3 and an additional 13-amino-acid N-terminal extension. These modifications reduce its binding to IGF-binding proteins, leaving more of the molecule free to activate IGF-1 receptors — the basis for its greater potency than native IGF-1 in cell and animal studies. (Vendor materials commonly cite a circulating half-life of "20–30 hours," but no published human pharmacokinetic study supports a specific figure — treat that number as unverified.) IGF-1 LR3 is not approved for any medical indication and is sold as a research-use-only compound by third-party laboratories. The compound is a downstream peptide that bypasses the pituitary GH axis entirely.

What is IGF-1 LR3 and how does the modified IGF-1R agonist mechanism work?

IGF-1 LR3 is a synthetic analog of human IGF-1 with two structural modifications: an arginine substitution replacing glutamate at position 3 (reducing IGFBP-3 binding affinity), and a 13-amino-acid N-terminal extension (further reducing IGFBP binding and extending circulation time). The result is a peptide that directly activates IGF-1 receptors throughout the body. Its reduced IGF-binding-protein affinity increases the fraction of free, receptor-active peptide; a specific in-vivo half-life is not established in published human data (the widely repeated "20–30 hours" is vendor-sourced, not from peer-reviewed pharmacokinetics). Unlike GHRH analogs and GHRPs, IGF-1 LR3 bypasses the pituitary axis entirely.

Source: Recombinant Human LR3 IGF-I/IGF-1 GMP Protein, CF — datasheet (cat 8335D-GMP), R&D Systems (Bio-Techne), R&D Systems (manufacturer datasheet), 2026 · Evidence level: preclinical extensive (cell culture, rodent muscle and metabolic models); limited human clinical data

What does the research show for IGF-1 LR3?

Preclinical studies have demonstrated robust effects on muscle protein synthesis, satellite cell activation, glucose uptake, and tissue proliferation in cell culture and rodent models. Published human clinical trial data is sparse — IGF-1 LR3 has been studied as a research reagent more than as a therapeutic candidate. Native IGF-1 (mecasermin, Increlex) is FDA-approved for severe primary IGF-1 deficiency, but IGF-1 LR3 itself is not.

Evidence level: preclinical extensive; native IGF-1 (mecasermin) FDA-approved for primary IGFD; IGF-1 LR3-specific human data limited

How does IGF-1 LR3 compare to GH-releasing peptides?

IGF-1 LR3 acts downstream of the GH axis — it directly activates IGF-1 receptors without requiring pituitary stimulation, unlike GHRH analogs (which work upstream at the GHRH receptor) and GHRPs (which work at the ghrelin receptor). This means IGF-1 LR3's effects are not subject to feedback regulation through the pituitary axis, and IGF-1 elevation is direct rather than mediated by endogenous GH pulses.

What are the documented side effects of IGF-1 LR3?

Direct IGF-1 receptor activation can produce hypoglycemia (IGF-1R has structural similarity to insulin receptors), particularly at higher doses or in fasted states. Sustained IGF-1 elevation raises theoretical concerns about cancer risk through the IGF-1 axis's role in cell proliferation, though IGF-1 LR3-specific long-term human data is absent. Injection-site reactions, transient headache, and mild lethargy are reported in community research use.

Evidence level: theoretical (IGF-1 axis biology); native IGF-1 (mecasermin) clinical safety data; IGF-1 LR3-specific long-term data unestablished

What is the regulatory status of IGF-1 LR3?

IGF-1 LR3 is not approved for any medical indication anywhere in the world as of August 2026. Native IGF-1 (mecasermin, Increlex) is FDA-approved for severe primary IGF-1 deficiency, but the modified LR3 analog has no approval. IGF-1 LR3 is sold strictly as a research-use-only compound by third-party laboratories. Regulatory context in are peptides legal regulatory status by country.

Source: INCRELEX (mecasermin) injection — US Prescribing Information, Ipsen (labeler), via FDA (Drugs@FDA)

Why does IGF-1 LR3 vendor verification matter?

IGF-1 LR3 is a modified IGF-1 — the 70-residue IGF-1 sequence carrying an Arg³-for-Glu³ substitution plus a 13-residue N-terminal extension — with a mass of about 9,111 Da measured by mass spectrometry on the manufacturer's reference material (versus roughly 7.6 kDa for native IGF-1). Because the two masses differ, mass-spectrometry identity confirmation is the check that separates genuine IGF-1 LR3 from native IGF-1, DES(1-3) IGF-1, or mecasermin, and endotoxin testing matters for a recombinant E. coli-derived protein. Guidance in how-to-test-peptides hub.

Source: Recombinant Human LR3 IGF-I/IGF-1 GMP Protein, CF — datasheet (cat 8335D-GMP), R&D Systems (Bio-Techne), R&D Systems (manufacturer datasheet), 2026

How does Peptigrity verify IGF-1 LR3 vendors?

Peptigrity collects independent third-party Certificates of Analysis for IGF-1 LR3 from shops' official channels and verifies each for authenticity before publishing. Because shops choose which COAs to publish, results reflect the batches shops have made public rather than every production batch — a selection bias we state openly. A community-funded Testing Grant to purchase and test vials anonymously is in development. HPLC purity, mass-spectrometry identity (target mass ≈ 9,111 Da), and endotoxin testing are the checks that matter most for this recombinant protein. Tests in the database come from independent labs such as Janoshik Analytical, Freedom Diagnostics, and Chromate. The lab test table above this section shows the cross-shop dataset. Methodology in how we calculate trust scores.

Frequently asked questions

Is IGF-1 LR3 the same as native IGF-1?

No. IGF-1 LR3 has two structural modifications relative to native IGF-1 — an arginine substitution at position 3 and a 13-amino-acid N-terminal extension — that reduce IGF-binding-protein binding, which raises the free, receptor-active fraction and increases potency relative to native IGF-1. A specific extended half-life ("20–30 hours") is often quoted by vendors but is not established in published human pharmacokinetic data. Native IGF-1 is FDA-approved as mecasermin (Increlex) for severe primary IGF-1 deficiency; IGF-1 LR3 is not approved.

Source: INCRELEX (mecasermin) injection — US Prescribing Information, Ipsen (labeler), via FDA (Drugs@FDA)

How does IGF-1 LR3 differ from IGF-1 DES?

IGF-1 LR3 carries an Arg³ substitution and a 13-residue N-terminal extension that lower IGF-binding-protein affinity for broader, systemic receptor activity; its often-quoted "20–30 hour" half-life is vendor-sourced and not established in human pharmacokinetic data. IGF-1 DES is a truncated variant with very short half-life and primarily local anabolic activity at the injection site. They are used for different research applications — LR3 for systemic IGF-1R activation, DES for local muscle research.

Is IGF-1 LR3 legal to purchase?

IGF-1 LR3 is legal to purchase as a research chemical for laboratory use in most jurisdictions, but it is not approved for human consumption. Country breakdown in peptide legal status guide.

Does IGF-1 LR3 carry cancer risk?

Sustained IGF-1 elevation through any mechanism raises theoretical cancer concerns because the IGF-1 axis is implicated in cell proliferation pathways. IGF-1 LR3-specific long-term human data is absent. Native IGF-1 (mecasermin, Increlex) has no boxed warning, but its label does carry a Malignant Neoplasia warning (§5.7) among its Warnings and Precautions. Anyone considering use should consult a licensed physician about the underlying axis biology.

Source: INCRELEX (mecasermin) injection — US Prescribing Information, Ipsen (labeler), via FDA (Drugs@FDA)

Does IGF-1 LR3 show up on a drug test?

Yes. IGF-1 and analogs are on the WADA Prohibited List under S2.3 (Growth Factors and Growth Factor Modulators) — "Insulin-like growth factor 1 (IGF-1, mecasermin) and its analogues" — and prohibited at all times. Detection methods have improved. For drug-testing context, see do peptides show up on drug tests.

Source: WADA Prohibited List (current year)

How can I verify an IGF-1 LR3 vendor is selling real product?

Independent third-party HPLC certificate of analysis from a lab the vendor does not own or pay, with mass spectrometry identity confirmation (expected MW ~9,111 Da) and endotoxin testing. The peptide's size makes purity and endotoxin verification particularly critical. COA interpretation in red flags in peptide certificates of analysis.

Does Peptigrity recommend an IGF-1 LR3 dose?

No. IGF-1 LR3 is not approved for human consumption and Peptigrity is an independent review platform, not a medical authority. Research-use dosing in community protocols varies, with hypoglycemia risk requiring particular caution. Anyone considering use should consult a licensed physician.

This section is for educational and informational purposes only and does not constitute medical advice. IGF-1 LR3 is not approved by the FDA or any other regulator for human use. Always consult a qualified healthcare provider before using any peptide or research compound. Peptigrity is an independent review platform and does not sell, endorse, or recommend specific products or vendors.